Time to revolutionize the triggering of ovulation.

Area of Science:

• Reproductive Endocrinology
• Infertility Treatments
• Hormone Therapy

Background:

• Ovarian stimulation methods are evolving with gonadotrophin advancements.
• Luteinizing hormone (LH) plays a key role in natural ovulation and luteinization.
• Current ovulation induction often relies on human chorionic gonadotrophin (HCG) or gonadotrophin-releasing hormone agonists.

Purpose of the Study:

• To highlight the importance of LH in ovulation induction.
• To advocate for increased attention to LH use in assisted reproduction.
• To discuss the potential of recombinant LH (LHr) as a safer alternative to HCG.

Main Methods:

• Commentary based on current understanding of LH physiology and gonadotrophin therapy.
• Review of the characteristics of the endogenous LH surge.
• Evaluation of recombinant LH (LHr) availability and potential applications.

Main Results:

• The endogenous LH surge has balanced characteristics for ovulation and luteinization without causing ovarian hyperstimulation.
• Recombinant LH (LHr) offers an escape from urinary HCG, potentially avoiding its risks and side effects.
• Current high doses of LHr are needed to mimic endogenous LH surge events.

Conclusions:

• Further research is needed to optimize recombinant LH (LHr) properties to replicate endogenous LH surges.
• Developing LHr that can induce ovulation surges would improve patient safety and luteal phase function.
• This advancement could replace HCG, mitigating risks of ovarian hyperstimulation and luteal phase anomalies.